Trinity Biotech Preliminary Q2 2024 Revenue $15.5M-$16M; Entered Into MedScience Distribution Agreement In UK Effective As Of August 1, 2024 Which Encompasses Clinical Chemistry, Infectious Disease, And Autoimmune Product
Portfolio Pulse from Benzinga Newsdesk
Trinity Biotech (NASDAQ: TRIB) announced preliminary Q2 2024 revenues of $15.5M-$16M, reflecting significant year-over-year growth. The company also entered a distribution agreement with MedScience in the UK, effective August 1, 2024, covering clinical chemistry, infectious disease, and autoimmune products.
August 02, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Trinity Biotech announced preliminary Q2 2024 revenues of $15.5M-$16M, showing significant growth from $13.9M in Q2 2023. The company also entered a distribution agreement with MedScience in the UK, effective August 1, 2024, covering clinical chemistry, infectious disease, and autoimmune products.
The significant year-over-year revenue growth and the new distribution agreement in the UK are positive indicators for Trinity Biotech. The revenue growth demonstrates strong business performance, while the distribution agreement could expand market reach and sales in the UK.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100